Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Nephrology
Published in: Journal of Nephrology 4/2016

01-08-2016 | Review

IgM nephropathy: is it closer to minimal change disease or to focal segmental glomerulosclerosis?

Authors: R. Brugnano, R. Del Sordo, C. Covarelli, E. Gnappi, S. Pasquali

Published in: Journal of Nephrology | Issue 4/2016

Login to get access

Abstract

Immunoglobulin (Ig)M nephropathy (IgMN), known since 1978, is a very controversial clinicopathological entity characterized by IgM diffuse deposits in the mesangium at immunofluorescence whereas light microscop identifies minimal glomerular lesion, hypercellularity and expansion of the mesangium or sclerotic focal, segmental lesion. Clinically, it is a nephrotic syndrome, especially in pediatric patients, or asymptomatic proteinuria and/or isolated hematuria. These characteristics narrowly define IgMN between minimal change disease and focal segmental glomerulosclerosis, so it is not often recognized as a separate pathology. Homogeneous epidemiologic, pathogenetic, clinical or histological data are not available. Recent research on the pathogenetic role of mesangial IgM has, however, renewed interest in IgMN and naturally the controversies.
Literature
1.
Cohen AH, Border WA, Glassock RJ (1978) Nephrotic syndrome with glomerular mesangial IgM deposits. Lab Invest 38:610–619PubMed
2.
Bhasin HK, Abuelo JG, Nayak R, Esperaza AR (1978) Mesangial proliferative glomerulonephritis. Lab Invest 39:21–29PubMed
3.
Vangelista A, Frasca G, Biagini G, Bonomini V (1981) Long term study of mesangial proliferative glomerulonephritis with IgM deposits. Proc Eur Dial Transpl Assoc 18:503–507
4.
Cavallo T, Johnson MP (1981) Immunopathologic study of minimal change glomerular disease with mesangial IgM deposits. Nephron 27(6):281–284CrossRefPubMed
5.
Cohen AH, Border WA (1982) Mesangial proliferative glomerulonephritis. Semin Nephrol 2:228–240
6.
7.
Mubarak M, Kazi JI, Shakeel S, Lanewala A, Hashmi S, Akhter F (2011) Clinicopathologic characteristics and steroid response of IgM nephropathy in children presenting with idiopathic nephrotic syndrome. APMIS 119:180–186CrossRefPubMed
8.
Singhai AM, Vanikar AV, Goplani KR, Kanodia KV, Patel RD, Suthar KS et al (2011) Immunoglobulin M nephropathy nephropathy in adults and adolescents in India: a single-center study of natural history. Indian J Pathol Microbiol 54(1):3–6CrossRefPubMed
9.
Schena FP (1997) Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. Nephrol Dial Transplant 12:418–426CrossRefPubMed
10.
Gesualdo L, Di Palma AM, Morrone LF, Strippoli GF, Schena FP, Italian Immunopathology Group, Italian Society of Nephrology (2004) The Italian experience of the national registry of renal biopsies. Kidney Int 66(3):890–894CrossRefPubMed
11.
Parichatikanond P, Chawanasuntorapoj R et al (2006) An Analysis of 3555 cases of renal biopsy inThailand. J Med Assoc Thai 89(Suppl. 2):S106–S111PubMed
12.
Border WA (1988) Distinguishing minimal-change disease from mesangial disorder. Kidney Int 34:419–434CrossRefPubMed
13.
Kashgarian M (1985) Mesangium and glomerular disease. Lab Invest 52:569–571PubMed
14.
Vilches AR, Turner DR, Cameron JS, Ogg CS, Clantler C, Williams DG (1982) Significance of mesangial IgM deposition in minimal change nephrotic syndrome. Lab Invest 46:10–15PubMed
15.
Ji-Yun Y, Melvin T, Sibley R, Michael AP (1984) No evidence for a specific role of IgM in mesangial proliferation of idiopathic nephrotic syndrome. Kidney Int 25:100–106CrossRefPubMed
16.
Fogo AB (2001) Minimal change disease and focal segmental glomerulosclerosis. Nephrol Dial Transplant 16:74–76CrossRefPubMed
17.
Hsu HC, Chen WY, Lin GJ, Chen L, Kao SL, Huang CC, Lin CY (1984) Clinical and immunopathologic study of mesangial IgM nephropathy: report of 41 cases. Histopathology 8:435–446CrossRefPubMed
18.
International Study of kidney disease in Children (1974) Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Lancet 2:423–427
19.
Myllymäki J, Saha H, Mustonen J, Helin H, Pasternack (2003) IgM nephropathy: clinical picture and long-term prognosis. Am J Kidney Dis 41(2):343–350CrossRefPubMed
20.
Mubarak M, Kazi JI (2012) IgM nephropathy revisited. Nephro-Urol Mon 4:603–608CrossRef
21.
Mokhtar GA (2011) IgM nephropathy: clinical picture and pathological findings in 36 patients. Saudi J Kidney Dis Transpl 22:969–975PubMed
22.
Saha H, Mustonen J, Pastermack A, Helin H (1989) Clinical follow-up of 54 patients with IgM nephropathy. Am J Nephrol 9:124–128CrossRefPubMed
23.
O’Donoghue DJ, Lawler W, Hunt LP, Acheson EJ, Mallick NP (1991) IgM associated primary diffuse mesangial proliferative glomerulonephritis: natural history and prognostic indicators. Q J Med 79(288):333–350PubMed
24.
Kazi J, Mubarak M (2014) IgM nephropathy presenting as full blown crescentic glomerulonephritis: first report in the literature. Nefrologia 34(3):423–424PubMed
25.
Zeis PM, Kavazarakis E, Nakopoulou L, Moustaki M, Messaritaki A, Zeis MP et al (2001) Glomerulopathy with mesangial IgM deposits: long-term follow up of 64 children. Pediatr Int 43(3):287–292CrossRefPubMed
26.
Kanemoto K, Ito H, Anzai M, Matsumura C, Kurayama H (2013) Clinical significance of IgM and C1q deposition in the mesangium in pediatric idiopathic nephrotic syndrome. J Nephrol 26(2):306–314CrossRefPubMed
27.
Vanikar AV, Kanodia KV, Patel RD, Suthar KS, Patel HV, Gumber MR, Trivedi HL (2012) IgM Nephropathy in India: a single centre experience. Indian J Pediatr 79(8):1025–1027CrossRefPubMed
28.
Spreitzer MV, Vizjak A, Ferluga D, Kenda RB, Kersnik Levart T (2014) Do C1q or IgM nephropathies predict disease severity in children with minimal change nephrotic syndrome? Pediatr Nephrol 29(1):67–74CrossRef
29.
Kopolovic J, Shvil Y, Pomeranz A, Ron N, Rubinger D, Oren R (1987) IgM nephropathy: morphological study related to clinical findings. Am J Nephrol 7:275–280CrossRefPubMed
30.
Mubarak M, Naqvi R, Kazi JI, Shakeel S (2013) Immunoglobulin M nephropathy in adults: a clinicopathological study. Iran J Kidney Dis 7:214–219PubMed
31.
32.
Prasad DR, Zimmerman SW, Barkholder PM (1977) Immunohistologic features of minimal change nephrotic syndrome. Arch Pathol Lab Med 101:345–349PubMed
33.
Al-Eisa A, Carter JE, Lirenman DS, Magil AB (1996) Childhood IgM nephropathy: comparison with minimal change disease. Nephron 72:37–43CrossRefPubMed
34.
Swartz SJ, Eldin KW, Hicks MJ, Feig DI (2009) Minimal change disease with IgM+ immunofluorescence: a subtype of nephrotic syndrome. Pediatr Nephrol 24:1187CrossRefPubMed
35.
Salmon AHJ, Kamel D, Mathiedon PW (2004) Recurrence of IgM nephropathy in a renal allograft. Nephrol Dial Transplant 19:2650–2652CrossRefPubMed
36.
Westphal S, Hansson S, Mjornsted L, Molne J, Swerkersson S, Friman S (2006) Early recurrence of nephrotic syndrome (immunoglobulin m nephropathy) after renal transplantation successfully treated with combinations of plasma exchanges, immunoglobulin, and rituximab. Transplant proc 38(8):2659–2660CrossRefPubMed
37.
Betjes MG, Roodnat JI (2009) resolution of IgM nephropathy after rituximab treatment. Am J Kidney Dis 53(6):1059–1062CrossRefPubMed
38.
D’Agati VD, Kaskel FJ, Falk Ronald J (2011) Focal Segmental Glomerulosclerosis. N Engl J Med 365:2398–2411CrossRefPubMed
39.
Weening JJ, Ronco P, Remuzzi G (2013) Advances in the pathology of the glomerular diseases. In: Chen N (ed) New Insights into Glomerulonephritis. Contrib Nephrol, vol 181. Karger, Basel, pp 12–21CrossRef
40.
Den Berg Van, Jg Weening JJ (2004) Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome. Clin Sci 107:125–136CrossRefPubMed
41.
Strassheim D, Renner B, Panzer S, Fuquay R, Kulik L, Ljubanović D, Holers VM, Thurman JM (2013) IgM contributes to glomerular injury in FSGS. J Am Soc Nephrol 24(3):393–406CrossRefPubMedPubMedCentral
42.
Thurman JM, Wong M, Renner B, Frazer-Abel A, Giclas PC, Joy MS, Jalal D, Radeva MK, Gassman J, Gipson DS, Kaskel F, Friedman A, Trachtman H (2015) Complement activation in patients with focal segmental glomerulosclerosis. PLoS One 10(9):e0136558CrossRefPubMedPubMedCentral
43.
Panzer SE, Laskowski J, Renner B, Kulik L, Ljubanovic D, Huber KM, Zhong W, Pickering MC, Holers VM, Thurman JM (2015) IgM exacerbates glomerular disease progression in complement-induced glomerulopathy. Kidney Int 88:528–537CrossRefPubMedPubMedCentral
Metadata
Title
IgM nephropathy: is it closer to minimal change disease or to focal segmental glomerulosclerosis?
Authors
R. Brugnano
R. Del Sordo
C. Covarelli
E. Gnappi
S. Pasquali
Publication date
01-08-2016
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 4/2016
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-016-0269-6

Other articles of this Issue 4/2016

Journal of Nephrology 4/2016 Go to the issue

Review

Remission and withdrawal of therapy in lupus nephritis

Editorial

Up-to date of glomerular disease

Review

Treatment of IgA nephropathy with renal insufficiency

Review

IgA nephropathy and infections

Original Article

Montelukast as an add-on treatment in steroid dependant nephrotic syndrome, randomised-controlled trial

Original Article

Long-term outcome of IgA nephropathy with minimal change disease: a comparison between patients with and without minimal change disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits